Long-term Anticoagulation in a Patient With Severe Hemophilia A

University Hospital, Strasbourg, France1 enrolled

Overview

To date, and to our knowledge, no case of severe hemophilia A patients receiving long-term anticoagulation has been published. Severe hemophilia A is a hereditary bleeding disorder characterized by a factor VIII (FVIII) deficiency of \<1%. Anticoagulation remains a real challenge in these patients, given the precarious hemostatic balance between the bleeding risk associated with anticoagulation and the antithrombotic protection associated with factor VIII deficiency. The advent of new replacement therapies, characterized by FVIII molecules with a prolonged or very prolonged half-life, provides a high level of FVIII coverage (and therefore protection against the risk of bleeding) in patients receiving prophylaxis, thus facilitating the initiation of anticoagulation therapy.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Hemophilia A

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult patient (≥ 18 years) with severe hemophilia A * Absence of written objection in the subject's medical record to the reuse of their data for scientific research purposes. Exclusion Criteria: \- Subject having expressed objection to the reuse of their data for scientific research

Locations (1)

Laboratoire d'Hématologie - Unité d'Hémostase - CHU de Strasbourg - France

Outcomes

Primary Outcomes

FVIII Level

Factor VIII (FVIII) is a clotting protein: it enables the blood to form a clot to stop bleeding. Its level indicates how well the blood clots, which is useful for diagnosing or monitoring hemophilia A before surgery. General values: * Normal: approximately 50 to 150% * Too low: risk of bleeding * Too high: may increase the risk of clots

Time frame: Up to 15 months